Immuneering (IMRX) Stock Forecast & Price Target

$2.00 +0.16 (+8.70%)

(As of 12/20/2024 05:31 PM ET)

Immuneering - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 8 Analyst Ratings

Sell
1

Hold
3

Buy
4

Based on 8 Wall Street analysts who have issued ratings for Immuneering in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 1 has given a sell rating, 3 have given a hold rating, and 4 have given a buy rating for IMRX.

Consensus Price Target

$12.80
540.00% Upside

According to the 8 analysts' twelve-month price targets for Immuneering, the average price target is $12.80. The highest price target for IMRX is $25.00, while the lowest price target for IMRX is $3.00. The average price target represents a forecasted upside of 540.00% from the current price of $2.00.

Get the Latest News and Ratings for IMRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Immuneering and its competitors.

IMRX Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$12.80	$12.80	$12.60	$20.20
Forecasted Upside	540.00% Upside	506.64% Upside	292.52% Upside	188.57% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Moderate Buy

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

IMRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Immuneering Stock vs. The Competition

Type	Immuneering	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	540.00% Upside	25,828.59% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent IMRX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
12/13/2024	Morgan Stanley 3 of 5 stars	Downgrade	Equal Weight ➝ Underweight
11/20/2024	Chardan Capital 1 of 5 stars	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00	+537.25%
11/14/2024	Needham & Company LLC 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00	+777.19%
4/2/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$20.00 ➝ $8.00	+190.91%
3/15/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
3/15/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$16.00 ➝ $3.00	+3.45%
Get the Latest News and Ratings for IMRX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.
3/14/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
3/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$25.00	+306.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:55 PM ET.

IMRX Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Immuneering is $12.80, with a high forecast of $25.00 and a low forecast of $3.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There is currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IMRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMRX, but not buy additional shares or sell existing shares.
: According to analysts, Immuneering's stock has a predicted upside of 540.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Immuneering's stock had 1 downgrade by analysts.
: Immuneering has been rated by research analysts at Chardan Capital, Morgan Stanley, and Needham & Company LLC in the past 90 days.
: Analysts like Immuneering less than other "medical" companies. The consensus rating for Immuneering is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IMRX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

👉[Click here to get your FREE report delivered instantly!]

This page (NASDAQ:IMRX) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Stock Forecast & Price Target